<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119053</url>
  </required_header>
  <id_info>
    <org_study_id>01VNS2009</org_study_id>
    <nct_id>NCT01119053</nct_id>
  </id_info>
  <brief_title>Effects of Vagus Nerve Stimulation (VNS) as a Treatment of Persistent Depression With Comorbid Personality Disorders (Impulse-VNS</brief_title>
  <acronym>Impuls-V</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Goettingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this monocentre two-armed double blind randomised placebo-controlled study - in which the&#xD;
      control group obtains the VNS therapy within a defined space of time after 12 weeks - the&#xD;
      impact of vagus nerve stimulation on depressive symptomatology of patients with&#xD;
      therapy-resistant depressive personality disorders shall be analysed. Particularly in&#xD;
      comorbid disorders, medicamentous treatment shows exceedingly bad response rates. Against the&#xD;
      background of hitherto insufficient treatment strategies for chronic or persistent depression&#xD;
      with comorbidities, the proceeding of a study on the effects of VNS on depressive patients&#xD;
      with comorbid disorders is absolutely essential.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To analyse whether VNS is effective within the therapy of depression with comorbid personality disorders</measure>
    <time_frame>6 Month</time_frame>
    <description>The primary objective of this study is to analyse whether VNS is effective within the therapy of depression with comorbid personality disorders.&#xD;
It shall be verified, as a primary hypothesis, whether VNS with ongoing stimulation is significantly predominant to a non-stimulating control with respect to reducing depressive symptomatology (for differences within HAM-D score and the response rate as the percentage of patients with a reduction in the HAM-D score of at least 50%, week 1 - week 12, see flow-chart).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acquisition of Alteration by means of BDI, TMT-A and B, WMS R, VLMT; WHO-QoL, GAF, CGM, SDS</measure>
    <time_frame>6 month</time_frame>
    <description>Acquisition of the improvement of self-rated depressiveness (BDI), stress axis (cortisol of neurocognition, quality of life (WHO-QoL) and impairment through disease (GAF, CGI, SDS), examination of brain structural and functional parametres as predictors for therapy response (VBM-MRT), Region of Interest Approach and proton magnetic resonance spectroscopy, diagnostic TMS (dTMS) in the beginning of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Depression</condition>
  <condition>Comorbid Personality Disorders</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>In this branch of study, study participants obtain the VNS therapy after a defined space of time of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within this space of time, study participants obtain the VNS therapy at once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VNS Pulse Model 102</intervention_name>
    <description>Individual dosage within the realm of 0,25 mA - 3,5 mA. Uninterrupted stimulation of 24 h.</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VNS Pulse Model 102</intervention_name>
    <description>Within this branch, study participants obtain the VNS therapy after a defined space of time of 12 weeks.</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  embedding criteria according to &quot;VNS manual for doctors&quot;&#xD;
&#xD;
          -  diagnosis of a recurrent depressive disorder (based on ICD-10 criteria) and a comorbid&#xD;
             personality disorder (according to SKID I/II) with an ailment period of more than six&#xD;
             months&#xD;
&#xD;
          -  age 18-80 years&#xD;
&#xD;
          -  verbal IQ (WST) 85 points&#xD;
&#xD;
          -  HAM-D sum score &gt; 20 points&#xD;
&#xD;
          -  at least four depressive episodes in the anamnesis&#xD;
&#xD;
          -  no amelioration of current depressive episodes under two different antidepressants in&#xD;
             appropriate dosage for six weeks&#xD;
&#xD;
          -  constant medication within the last two weeks (at the discretion of the supervising&#xD;
             doctor)&#xD;
&#xD;
          -  written consent after informing the patient about the study&#xD;
&#xD;
          -  no VNS treatment to date&#xD;
&#xD;
          -  no misuse of illegal drugs or alcohol&#xD;
&#xD;
          -  Women in childbearing age are not permitted to participate in the study if a doctor&#xD;
             has asserted the non-existence of pregnancy before the beginning of the study.&#xD;
             Furthermore, the procedure of a pregnancy test is recommended after the completion of&#xD;
             the study. During the study, a reliable type of contraception (such as the Pill)&#xD;
             should be taken. The doctor provides further information.&#xD;
&#xD;
        Exclusion criteria according to &quot;VNS manual for the doctor&quot;&#xD;
&#xD;
          -  present hospitalisation according to the federal states' PsychKG&#xD;
&#xD;
          -  clinically relevant unstable bodily concomitant diseases&#xD;
&#xD;
          -  former VNS treatment&#xD;
&#xD;
          -  reduction of intelligence with verbal IQ &lt; 85 (WST)&#xD;
&#xD;
          -  conceivable use of an MRT examination after the implantation of the VNS-system&#xD;
&#xD;
          -  for diagnostic examinations with the dTMS and the MRT: electric devices (such as&#xD;
             cardiac pacemakers, medicine pumps etc.) or pieces of metal (ferromagnetic, e.g.&#xD;
             screws after bone fractures) within or at the body, or large-scale tattoos&#xD;
&#xD;
          -  conditions that do not allow to use VNS, such as relevant dysfunctions of the heart's&#xD;
             stimulus conduction system or cardiac arrhythmia, stomach ulcer, dysphagia, palsy of&#xD;
             parts of the n-vagus nerve&#xD;
&#xD;
          -  insufficient knowledge of the German language&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  current misuse of substances&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Falkai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Psychiatry and Psychotherapy (University Medical Centre Goettingen, Germany)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claus Wolff-Menzler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Psychiatry and Psychotherapy (University Medical Centre Goettingen, Germany)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claus Wolff-Menzler, MD</last_name>
    <phone>+49 551 39 6610</phone>
    <email>cwolff@gwdg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Wobrock, MD</last_name>
    <phone>+49 551 39 6610</phone>
    <email>twobroc@gwdg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy (University Medical Centre)</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Wolff-Menzler, MD</last_name>
      <phone>+49 551 39 6610</phone>
      <email>cwolff@gwdg.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Wobrock, MD</last_name>
      <phone>+49 551 39 6610</phone>
      <email>twobroc@gwdg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Claus Wolff-Menzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Wobrock, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alkomiet Hasan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.psychiatrie.med.uni-goettingen.de/</url>
    <description>Dept. of Psychiatry and Psychotherapy (University Medical Centre Goettingen)</description>
  </link>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <last_update_submitted>June 28, 2010</last_update_submitted>
  <last_update_submitted_qc>June 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>University Medical Center Goettingen</name_title>
    <organization>Dept. of Psychiatry and Psychotherapy</organization>
  </responsible_party>
  <keyword>VNS</keyword>
  <keyword>Depression</keyword>
  <keyword>Personality-Disorder</keyword>
  <keyword>Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

